Merus Labs International Inc. Form 6-K April 20, 2012

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of **April**, **2012** 

Commission File No. 00-30082

# MERUS LABS INTERNATIONAL INC.

(Translation of registrant's name into English)

Suite 2007, 1177 West Hastings Street Vancouver, BC V6E 2K3

(Address of principal executive office)

Indicate by check mark whether the registrant files or will Form 20-F [X]	ll file annual reports under cover of Form 20-F or Form 40-l Form 40-F [ ]
·	ne Form 6-K in paper as permitted by Regulation S-T Rule b)(1) [ ]
	ne Form 6-K in paper as permitted by Regulation S-T Rule b)(7) [ ]

- 2 -

# SUBMITTED HEREWITH

Exhibits	
<u>99.1</u>	Notice of Change of Auditor
99.2	New Auditor Letter
99.3	Old Auditor Letter
<u>99.4</u>	Material Change Report dated April 18, 2012
<u>99.5</u>	News Release dated April 16, 2012

## Edgar Filing: Merus Labs International Inc. - Form 6-K

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: April 20, 2012

### MERUS LABS INTERNATIONAL INC.

/s/ Andrew Patient

Andrew Patient Chief Financial Officer